Source - SMW
Horizon Discovery Group  will deploy its CRISPR-based screening platform to identify novel targets for rare genetic diseases in a new collaboration with Fulcrum Therapeutics.

  The programme will initially focus on genetic diseases where no effective treatment options currently exist. 

Horizon's CRISPR-based screening platform, sophisticated bioinformatics, and cell line libraries provide a novel and highly efficient way to examine the regulation of genes and their role in disease.  

In this collaboration, Horizon will apply its platform and extensive know-how to identify novel gene regulation targets for further exploration by Fulcrum for the development of next-generation therapies.

The work will be engaged under a Full-time Equivalent (FTE) plus consumables model in a programme expected to run between five and seven months. Fulcrum has chosen Horizon as its preferred CRISPR-based screening platform service provider, and there is potential for further screens to identify targets for additional rare diseases after this initial programme.




Related Charts

Horizon Discovery Group (HZD)

0.00p (0.00%)
delayed 07:57AM